

## 1. Patient Details

Name		Date of birth	
Address		Telephone No.	
		Medicare No.	
Weight	kg	Height	cm/feet
		<input type="checkbox"/> Diabetic? IDDM/NIDDM	

## 2. Examination - select **clinical indications** below

- PET with Low Dose CT only
- PET with diagnostic CT of:
- |                                |                                  |                                 |
|--------------------------------|----------------------------------|---------------------------------|
| <input type="checkbox"/> Chest | <input type="checkbox"/> Abdomen | <input type="checkbox"/> Pelvis |
| <input type="checkbox"/> Brain | <input type="checkbox"/> Neck    | <input type="checkbox"/> Other  |

## 3. Clinical Details (including primary site of disease)

## 4. Referrer To be reimbursable, Medicare requires PET scans be specialist referred.

Referrers Name	<input type="checkbox"/> Previous imaging
Signature	
Date	
Copies of report to	

## Clinical Indications

### All FDG Avid Cancers

- Initial staging (item 61612).
- Suspected residual, metastatic or recurrent (item 61614).

### Brain

- Alzheimer's Disease (item 61560).
- Amyloid PET (No Medicare rebate).
- Brain Tumour (item 61538).
- Epilepsy (item 61559).

### Breast Cancer

- Staging (Stage III) (item 61524).
- Suspected metastatic or recurrent (item 61525).

### Cervix Cancer

- Primary Staging (item 61571).
- Restaging (item 61575).

### Colorectal Cancer

- Suspected metastatic or recurrent (item 61541).

### Head & Neck Cancer

- Staging new or recurrent (item 61598).
- Residual suspected (item 61604).

### Infection & Inflammation

- PET CT during gallium supply disruption.

### Lymphoma

- Staging new or untreated (item 61620).
- Residual (item 61622).
- Restaging (item 61628).
- Pre Stem Cell transplant (item 61632).

### Lung

- Solitary nodule (item 61523).
- Staging NSCLC (item 61529).

### Melanoma

- Suspected metastatic or recurrent (item 61553).

### Neuroendocrine Imaging

- Gastroenteropancreatic tumour (item 61647).
- Neuroendocrine neoplasm (item 61530).

### Oesophageal or GEJ Cancer

- Staging (item 61577).

### Ovarian Cancer

- Suspected residual, metastatic or recurrent (item 61565).

### Sarcoma

- Staging (item 61640).
- Suspected residual or recurrent (item 61646).

### Squamous Cell Carcinoma

- Unknown primary (involves cervical nodes) (item 61610).

### PSMA Prostate Imaging

- Initial staging (item 61563).
- Restaging (item 61564).
- Assessment of suitability for Lutetium-177-PSMA (item 61528).

### Other indication

- \_\_\_\_\_

## Book your appointment

1800 375 663

## Locations

Kurralta Park  
520 South Road, Kurralta Park

SAHMRI  
North Terrace, Adelaide

Southern Specialist Centre  
Cnr Main South/O'Sullivan Beach  
Rds, Morphett Vale



## Upload referral form

[jonesradiology.com.au/  
upload-a-referral](https://jonesradiology.com.au/upload-a-referral)

Please bring this referral form,  
your Medicare card and your  
pension/health care card

Your doctor has recommended you use Jones Radiology. You may choose another provider however it is important to discuss this with your doctor first.

**PET Rebutable MBS Codes**
**All FDG Avid Cancers**

Initial staging & management	61612	Initial staging of cancer, for a patient who is considered suitable for active therapy, if: (a) the cancer is a typically FDG-avid cancer; and (b) there is at least 10% likelihood that a PET study result will inform a significant change in management for the patient. Applicable once per cancer diagnosis (R).
Suspected residual, metastatic or recurrent	61614	Following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent cancer in a patient who is undergoing, or is suitable for, active therapy.

**Brain**

Alzheimer's Disease	61560	Brain FDG PET for the diagnosis of Alzheimer's disease if, in consultation with a specialist, the clinical evaluation is equivocal, and Alzheimer's PET or SPECT has not been performed in the previous 12 months. (Allowed 3 per lifetime.)
Brain Tumour Epilepsy	61538	Brain FDG PET for suspected residual or recurrent malignant brain tumour on anatomical imaging, after definitive therapy (or during ongoing chemotherapy), in patients suitable for further therapy.
Epilepsy	61559	Brain FDG PET for evaluation of refractory epilepsy in patients being evaluated for surgery.

**Breast Cancer**

Staging	61524	FDG PET for staging locally advanced (Stage III) breast cancer in a patient suitable for therapy.
Suspected metastatic or recurrent	61525	FDG PET for suspected metastatic or locally/regionally recurrent breast carcinoma in a patient suitable for therapy.

**Cervix Cancer**

Initial staging	61571	FDG PET for staging of patients with histologically proven carcinoma of the uterine cervix at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent.
Further staging	61575	FDG PET for staging patients with confirmed local recurrence suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent.

**Colorectal Cancer**

Suspected residual, metastatic or recurrent	61541	FDG PET following initial therapy, for suspected residual, metastatic or recurrent colorectal carcinoma in patients suitable for therapy.
---	-------	---

**Head & Neck Cancer**

Staging new or recurrent	61598	FDG PET for staging biopsy-proven newly diagnosed or recurrent head and neck cancer.
Suspected residual	61604	FDG PET for suspected residual head and neck cancer after definitive treatment, in patients suitable for therapy.

**Infection & Inflammation [Gallium scan unable to be provided due to supply disruption]**

Gallium supply disruption	61527	Example uses: Fever of unknown origin, osteomyelitis, sarcoidosis, pneumoconiosis, TB, retroperitoneal fibrosis, vasculitis, endocarditis, inflammatory bowel disease or abscess, non-specific tumour imaging.
---------------------------	-------	--

**Lymphoma**

Staging new or untreated	61620	FDG PET for initial staging of newly diagnosed or previously untreated Hodgkin or non-Hodgkin lymphoma.
Residual	61622	FDG PET to assess therapy response either during treatment or within three months of completing first line treatment for Hodgkin or non-Hodgkin lymphoma.
Restaging	61628	FDG PET for restaging following confirmation of Hodgkin or non-Hodgkin lymphoma recurrence.
Pre Stem Cell Transplant	61632	FDG PET to assess response to second-line chemotherapy if stem cell transplant is being considered for Hodgkin or non-Hodgkin lymphoma.

**Lung**

Solitary nodule	61523	FDG PET for evaluation of a solitary pulmonary nodule considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.
Staging	61529	FDG PET for staging proven non-small cell lung cancer, where curative surgery or radiotherapy is planned.

**Melanoma**

Suspected metastatic or recurrent	61553	FDG PET, following initial therapy, for suspected metastatic or recurrent melanoma in patients suitable for therapy.
-----------------------------------	-------	--

**Neuroendocrine**

Gastroenteropancreatic tumour	61647	Whole body 68Ga DOTA peptide PET study, if: (a) a gastro entero pancreatic neuroendocrine tumour is suspected on the basis of biochemical evidence with negative or equivocal conventional imaging; or (b) both: i) a surgically amenable gastro entero pancreatic neuroendocrine tumour has been identified on the basis of conventional techniques; and ii) the study is for excluding additional disease sites (R).
Neuroendocrine neoplasm	61530	Whole body 68Ga-DOTA-somatostatin receptor agonist PET study for: a) staging of histologically confirmed neuroendocrine neoplasm (NEN) considered surgically incurable on conventional imaging, or b) evaluation of somatostatin receptor expression of histologically confirmed and inoperable NEN, either locally advanced or metastatic, under consideration for peptide receptor radionuclide therapy (PRRT); or c) evaluation of response to PRRT therapy; or d) evaluation of suspected recurrent or metastatic disease in known somatostatin receptor positive NEN.

**Oesophageal or GEJ Cancer**

Staging	61577	FDG PET for staging proven oesophageal or GEJ carcinoma, in patients suitable for therapy.
---------	-------	--

**Ovarian Cancer**

Suspected residual, metastatic or recurrent	61565	FDG PET, following initial therapy, for suspected residual, metastatic or recurrent ovarian carcinoma in patients suitable for therapy.
---	-------	---

**Prostate**

Initial staging	61563	PSMA PET for initial staging of intermediate to high risk prostate cancer (Gleason score 7+ or PSA > 10ng/ml) in a previously untreated patient suitable for locoregional treatment with curative intent. (Allowed 1 per lifetime.)
Restaging	61564	PSMA PET for restaging of recurrence in a treated patient suitable for more locoregional treatment. (Allowed 2 per lifetime.) a) PSA increase of 2ng/ml above the nadir after radiotherapy treatment. b) Failure of PSA to fall to undetectable levels. c) Rising PSA after radical prostatectomy.
Assessment	61528	PSMA PET for the assessment of suitability for Lutetium 177 PSMA therapy in a patient with metastatic castrate resistant prostate cancer, after progressive disease has developed while undergoing prior treatment with at least one taxane chemotherapy and at least one androgen receptor signaling inhibitor.

**Sarcoma**

Staging	61640	FDG PET for initial staging of biopsy-proven sarcoma (excluding gastrointestinal stromal tumour), in patients considered by conventional staging to be potentially curable.
Suspected residual or recurrent	61646	FDG PET for suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after initial definitive therapy, to determine suitability for subsequent therapy with curative intent.

**Squamous Cell Carcinoma**

Unknown primary [involves cervical nodes]	61610	FDG PET for metastatic squamous cell carcinoma of unknown primary site involving cervical nodes.
---	-------	--